Atrium Therapeutics Inc(RNA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 3 at 4:01 PM ET (Korea 11/4 06:01)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 2.96% | Shs Outstand | 22.3M | Perf Week | 4.81% |
| Market Cap | 0.19B | Forward P/E | - | EPS next Y | -50.16% | Insider Trans | - | Shs Float | 21.6M | Perf Month | 9.41% |
| Enterprise Value | -0.07B | PEG | - | EPS next Q | -0.81 | Inst Own | 63.79% | Short Float | 17.24% | Perf Quarter | -25.72% |
| Income | - | P/S | - | EPS this Y | 4.12% | Inst Trans | -5.04% | Short Ratio | 13.21 | Perf Half Y | -32.46% |
| Sales | - | P/B | 0.7 | EPS next 5Y | -11.31% | ROA | - | Short Interest | 3.73M | Perf YTD | -40.19% |
| Book/sh | 12.54 | P/C | 0.74 | EPS past 3/5Y | -178.43% - | ROE | - | 52W High | -48% ($16.77) | Perf Year | - |
| Cash/sh | 11.86 | P/FCF | - | Sales past 3/5Y | 38.09% - | ROIC | - | 52W Low | 16.42% ($7.49) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 4.91% 4.63% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.41 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.73 | EPS Q/Q | -170.95% | Profit Margin | - | RSI (14) | 54.06 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.73 | Sales Q/Q | 90.97% | SMA20 | 7.5% ($8.11) | Beta | - | Target Price | $22 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/13 | SMA50 | -8.94% ($9.58) | Rel Volume | 1 | Prev Close | $8.55 |
| Employees | - | LT Debt/Eq | 0 | EPS/Sales Surpr. | 16.75% 350.58% | SMA200 | -27.55% ($12.04) | Avg Volume(3M) | 0.28M | Price | $8.72 |
| IPO | 2020/6/12 | Option/Short | No/Yes | Trades | 3379 | Volume | 280,932 | Change | 1.99% |
🧬 A US biotech company developing precision RNA therapeutics that target hereditary heart diseases. Leveraging a non-viral siRNA delivery platform that combines the tissue selectivity of antibody/targeted ligands with the precision of oligonucleotides, the company is building a drug pipeline in the field of precision cardiology.
Over the past 1 year, on the lower side
48% below its 1-year high.
Traded about as much as usual. That is 100% of its average volume.
Growth has stalled
Earnings are expected to grow by +4.1% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 63.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
JSML Janus Henderson Small Cap Growth Alpha ETF <0.01% 
GNOM Global X Genomics & Biotechnology ETF <0.01% 
EVNT AltShares Event-Driven ETF <0.01% 
MRGR ProShares Merger ETF <0.01% 
FSEG Fidelity Enhanced Small Cap Growth ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
VXUS Vanguard Total International Stock ETF 160.9B 
BNDX Vanguard Total International Bond ETF 84.8B 
SCHF Schwab International Equity ETF 67.8B 
IXUS iShares Core MSCI Total International Stock ETF 57.2B 
BIV Vanguard Intermediate-Term Bond ETF 28.7B It ranks #300 of 597 in the industry
Based on market cap of $194M.
PYXS#299 Pyxis Oncology Inc $196M PER - RNA#300 Atrium Therapeutics Inc $194M PER - 
RNAC#301 Cartesian Therapeutics Inc $194M PER - 
PRQR#302 ProQR Therapeutics N.V $193M PER - 
DTIL#303 Precision Biosciences Inc $192M PER - 
FAQ
What kind of company is RNA?
RNA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RNA?
The market cap of RNA is approximately $194M, ranking 4,021 within its sector.
What is the 52-week high and low for RNA?
RNA has recorded a 52-week high of $16.77 and a low of $7.49.
